AIM: This retrospective study aimed to evaluate the long-term response and toxicity of recurrent malignant glioma patients to inhalation chemotherapy with perillyl alcohol (POH). PATIENTS AND METHODS: The cohort included 117 men and 81 women with primary glioblastoma multiforme (GBM; n=154), grade III astrocytoma (AA; n=26) and anaplastic oligodendroglioma (AO; n=5). POH inhalation schedule 4-times daily started with 66.7 mg/dose; 266 mg/day and escalated up to 133.4 mg/dose; 533.6 mg/day. Clinical toxicity and overall survival following treatment were compared with tumor size, topography, extent of peritumoral edema and histological classification. RESULTS: Adhesion to the protocol was high (>95%), POH (533.6 mg/daily) occasionally caused nose soreness but rarely nosebleed. Tumor size, peritumoral edema and the oligodendroglial component influenced response to treatment. CONCLUSION: After 4 years under exclusive POH treatment, 19% of patients still remain in clinical remission. Long-term POH inhalation chemotherapy is a safe and non-invasive strategy efficient for recurrent malignant glioma.
AIM: This retrospective study aimed to evaluate the long-term response and toxicity of recurrent malignant gliomapatients to inhalation chemotherapy with perillyl alcohol (POH). PATIENTS AND METHODS: The cohort included 117 men and 81 women with primary glioblastoma multiforme (GBM; n=154), grade III astrocytoma (AA; n=26) and anaplastic oligodendroglioma (AO; n=5). POH inhalation schedule 4-times daily started with 66.7 mg/dose; 266 mg/day and escalated up to 133.4 mg/dose; 533.6 mg/day. Clinical toxicity and overall survival following treatment were compared with tumor size, topography, extent of peritumoral edema and histological classification. RESULTS: Adhesion to the protocol was high (>95%), POH (533.6 mg/daily) occasionally caused nose soreness but rarely nosebleed. Tumor size, peritumoral edema and the oligodendroglial component influenced response to treatment. CONCLUSION: After 4 years under exclusive POH treatment, 19% of patients still remain in clinical remission. Long-term POH inhalation chemotherapy is a safe and non-invasive strategy efficient for recurrent malignant glioma.
Authors: Michael D Prados; Sara A Byron; Nhan L Tran; Joanna J Phillips; Annette M Molinaro; Keith L Ligon; Patrick Y Wen; John G Kuhn; Ingo K Mellinghoff; John F de Groot; Howard Colman; Timothy F Cloughesy; Susan M Chang; Timothy C Ryken; Waibhav D Tembe; Jeffrey A Kiefer; Michael E Berens; David W Craig; John D Carpten; Jeffrey M Trent Journal: Neuro Oncol Date: 2015-05-01 Impact factor: 12.300
Authors: James C League-Pascual; Cynthia M Lester-McCully; Shaefali Shandilya; Lukas Ronner; Louis Rodgers; Rafael Cruz; Cody J Peer; William D Figg; Katherine E Warren Journal: J Neurooncol Date: 2017-03-13 Impact factor: 4.130
Authors: Dannielle H Upton; Caitlin Ung; Sandra M George; Maria Tsoli; Maria Kavallaris; David S Ziegler Journal: Theranostics Date: 2022-06-06 Impact factor: 11.600
Authors: Vinicius Vendrusculo; Vanessa P de Souza; Luiz Antônio M Fontoura; Marcelo G M D'Oca; Thais P Banzato; Paula A Monteiro; Ronaldo A Pilli; João Ernesto de Carvalho; Dennis Russowsky Journal: Medchemcomm Date: 2018-07-31 Impact factor: 3.597
Authors: Weijun Wang; Haiping He; Nagore I Marín-Ramos; Shan Zeng; Steven D Swenson; Hee-Yeon Cho; Jie Fu; Paul M Beringer; Josh Neman; Ligang Chen; Axel H Schönthal; Thomas C Chen Journal: Neuro Oncol Date: 2021-10-01 Impact factor: 12.300
Authors: Clovis Orlando da Fonseca; Himanshu Khandelia; Marcela D'Alincourt Salazar; Axel H Schönthal; Osório C Meireles; Thereza Quirico-Santos Journal: Surg Neurol Int Date: 2016-01-05
Authors: Priscila F de Aquino; Paulo Costa Carvalho; Fábio C S Nogueira; Clovis Orlando da Fonseca; Júlio Cesar Thomé de Souza Silva; Maria da Gloria da Costa Carvalho; Gilberto B Domont; Nilson I T Zanchin; Juliana de Saldanha da Gama Fischer Journal: Front Oncol Date: 2016-08-22 Impact factor: 6.244